Company: PSTV
Filing Date: 2025-03-04
Form Type: 8-K
Source: 0001193125-25-045305
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry Into a Material Definitive Agreement.  

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the “ Company”) entered into a securities purchase agreement (the “ Securities Purchase Agreement”) with accredited investors, including certain existing stockholders of the Company, identified on the signature page thereto (collectively, the “ Purchasers”) for a private placement of securities (the “ Private Placement”) for gross proceeds expected at closing of approximately $15.0 million. The Securities Purchase Agreement, provides for the sale and issuance by the Company of an aggregate of 28,042,140 shares (the “ Private Placement Shares”) of the Company’s common stock, par value $0.001 per share (“ Common Stock”), or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the “ Prefunded Warrants”), exercisable immediately at an exercise price of $0.001 per share (the “ Prefunded Warrant Shares”), with each Private Placement Share or Prefunded Warrant accompanied by (i) a Series A common warrant (the “ Series A Warrants”) to purchase one share of Common Stock (the “ Series A Warrant Shares”), and (ii) one Series B common warrant (the “ Series B Warrants”) to purchase one share of Common Stock (the “ Series B Warrant Shares,” and together with the Series A Warrant Shares, the “ Common Warrant Shares”). The Private Placement Shares, Prefunded Warrants, Prefunded Warrant Shares, Series A Warrants, Series B Warrants, and the Common Warrant Shares are collectively referred to herein as the “ Securities.”

The combined purchase price of $0.66 for each Private Placement Share or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represents the applicable “ Minimum Price” in accordance with Listing Rule 5635(d) of The Nasdaq Stock Market LLC (“ Nasdaq”).

The initial exercise price of each Series A Warrant issued in the Private Placement is $1.32 per share of Common Stock. The Series A Warrants are exercisable only following stockholder approval and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrant exercise price and the related number of shares of Common Stock issuable upon